The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical and translational study of p38 inhibitor pexmetinib plus nivolumab following anti–PD-1/L1 failure in advanced solid tumors.
 
Matthew Nguyen
No Relationships to Disclose
 
Andrew Poklepovic
Consulting or Advisory Role - IO Biotech
Speakers' Bureau - Natera
 
Hyun Lee
No Relationships to Disclose
 
Mark Jelinek
No Relationships to Disclose
 
Rebekah Dadey
No Relationships to Disclose
 
Mohammadreza Amjadzadeh
No Relationships to Disclose
 
Jason Luke
Stock and Other Ownership Interests - Actym Therapeutics; Kanaph Therapeutics; NeoTX; Onc.AI; Pyxis; Tempest Therapeutics
Consulting or Advisory Role - Abbvie; Alphamab; Bayer; Bright Peak Therapeutics; Bristol-Myers Squibb; Hotspot Therapeutics; Incyte; Merck; Novartis; Onc.AI; Pfizer; Regeneron; Tempest Therapeutics; Werewolf Therapeutics; Xilio Therapeutics
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Ikena Oncology (Inst); Immatics (Inst); Macrogenics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Numab (Inst); Takeda (Inst); Tizona Therapeutics, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Serial #15/612,657 (Cancer Immunotherapy),; Serial #PCT/US18/36052 (Microbiome Biomarkers for Anti-PD-1/PD-L1 Responsiveness: Diagnostic, Prognostic and Therapeutic Uses Thereof)
Travel, Accommodations, Expenses - Merck
 
Dan Zandberg
Consulting or Advisory Role - Bicara Therapeutics; Blueprint Medicines; Coherus Biosciences; Coherus Biosciences; InhibRx; Macrogenics; Merck; Prelude Therapeutics; Seagen
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); AVEO (Inst); Bicara Therapeutics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Macrogenics (Inst); Merck (Inst); Novasenta (Inst)
 
Riyue Bao
No Relationships to Disclose